RS49633B - Farmaceutske formulacije koje sadrže vorikonazol - Google Patents

Farmaceutske formulacije koje sadrže vorikonazol

Info

Publication number
RS49633B
RS49633B YUP-681/99A YU68199A RS49633B RS 49633 B RS49633 B RS 49633B YU 68199 A YU68199 A YU 68199A RS 49633 B RS49633 B RS 49633B
Authority
RS
Serbia
Prior art keywords
voriconazole
formulation according
formula
cyclodextrin
indicated
Prior art date
Application number
YUP-681/99A
Other languages
English (en)
Serbian (sr)
Inventor
Valerie Denise Harding
Original Assignee
Pfizer Inc.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10814734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS49633(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc., filed Critical Pfizer Inc.,
Publication of YU68199A publication Critical patent/YU68199A/sh
Publication of RS49633B publication Critical patent/RS49633B/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
YUP-681/99A 1997-06-21 1998-06-02 Farmaceutske formulacije koje sadrže vorikonazol RS49633B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9713149.4A GB9713149D0 (en) 1997-06-21 1997-06-21 Pharmaceutical formulations

Publications (2)

Publication Number Publication Date
YU68199A YU68199A (sh) 2002-06-19
RS49633B true RS49633B (sr) 2007-08-03

Family

ID=10814734

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-681/99A RS49633B (sr) 1997-06-21 1998-06-02 Farmaceutske formulacije koje sadrže vorikonazol

Country Status (47)

Country Link
US (1) US6632803B1 (https=)
EP (1) EP1001813B8 (https=)
JP (2) JP2000513029A (https=)
KR (1) KR100372988B1 (https=)
CN (1) CN1125653C (https=)
AP (1) AP912A (https=)
AR (1) AR015900A1 (https=)
AT (1) ATE238812T1 (https=)
AU (1) AU724799B2 (https=)
BG (1) BG64584B1 (https=)
BR (1) BRPI9809468B8 (https=)
CA (1) CA2295035C (https=)
CO (1) CO4940450A1 (https=)
CZ (1) CZ289570B6 (https=)
DE (1) DE69814091T2 (https=)
DK (1) DK1001813T3 (https=)
DZ (1) DZ2523A1 (https=)
EA (1) EA001924B1 (https=)
EG (1) EG23910A (https=)
ES (1) ES2195355T3 (https=)
GB (1) GB9713149D0 (https=)
HR (1) HRP980341B1 (https=)
HU (1) HU228338B1 (https=)
ID (1) ID22939A (https=)
IL (1) IL132918A (https=)
IS (1) IS2004B (https=)
MA (1) MA26508A1 (https=)
ME (1) ME00907B (https=)
MY (1) MY118151A (https=)
NO (1) NO313125B1 (https=)
NZ (1) NZ501066A (https=)
OA (1) OA11232A (https=)
PA (1) PA8453201A1 (https=)
PE (1) PE84899A1 (https=)
PL (1) PL191295B1 (https=)
PT (1) PT1001813E (https=)
RS (1) RS49633B (https=)
SA (1) SA98190159B1 (https=)
SI (1) SI1001813T1 (https=)
SK (1) SK282946B6 (https=)
TN (1) TNSN98090A1 (https=)
TR (1) TR199903191T2 (https=)
TW (1) TW406023B (https=)
UA (1) UA57083C2 (https=)
UY (1) UY25055A1 (https=)
WO (1) WO1998058677A1 (https=)
ZA (1) ZA985364B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818258D0 (en) * 1998-08-21 1998-10-14 Pfizer Ltd Antifungal compositions
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
PE20020578A1 (es) 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
ATE428423T1 (de) * 2002-08-20 2009-05-15 Bristol Myers Squibb Co Aripiprazol-komplex-formulierung und verfahren
GB0327390D0 (en) * 2003-11-25 2003-12-31 Pfizer Ltd Pharmaceutical formulations
WO2005055952A2 (en) * 2003-12-08 2005-06-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Synergistic anti-cancer compositions
CA2572223C (en) 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
US20070082870A1 (en) * 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
AR061889A1 (es) 2006-07-13 2008-10-01 Medichem Sa Proceso mejorado para la preparacion de voriconazol
CN1919846B (zh) * 2006-09-14 2013-01-02 大道隆达(北京)医药科技发展有限公司 伏立康唑及其药用盐、中间体的一种新定向合成制备方法
BG1110U1 (bg) * 2007-06-19 2008-09-30 Рудолф ПОДЛИПСКИ Отоплителен съд за експресно локално загряване навода
EP2018866A1 (en) * 2007-07-27 2009-01-28 Sandoz AG Pharmaceutical compositions containing voriconazole
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
US20110224232A1 (en) * 2008-05-06 2011-09-15 Board Of Regents, The University Of Texas System Treatment of Pulmonary Fungal Infection With Voriconazole via Inhalation
RU2472510C2 (ru) * 2008-06-06 2013-01-20 Гленмарк Фармасьютикалс Лимитед Стабильная лекарственная форма для местного применения, содержащая вориконазол
CN101390825B (zh) * 2008-10-01 2010-12-29 山东省眼科研究所 一种伏立康唑眼内释药系统
EP3090737A1 (en) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
CN101444510B (zh) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 含有伏立康唑的药物制剂及其制备方法
ES2573982T3 (es) 2009-08-19 2016-06-13 Ratiopharm Gmbh Proceso para la producción de coevaporados y complejos que comprenden voriconazol y ciclodextrina
WO2011064558A2 (en) 2009-11-30 2011-06-03 Cipla Limited Pharmaceutical composition
MX338685B (es) 2010-06-29 2016-04-26 Merck Sharp & Dohme Formulaciones de solucion intravenosa de posaconacol estabilizadas mediante beta-ciclodextrina sustituida.
EP2409699B1 (en) 2010-07-23 2014-04-30 Combino Pharm, S.L. Stable compositions of voriconazole
CN102058519B (zh) * 2010-11-19 2013-01-02 苏州特瑞药业有限公司 一种伏立康唑缓释栓剂及其制备方法
PL2720723T3 (pl) 2011-06-15 2018-10-31 Synthon Bv Stabilizowana kompozycja worykonazolu
EP2561863A1 (en) 2011-08-22 2013-02-27 Farmaprojects, S.A.U. Pharmaceutical compositions comprising voriconazole
WO2013109421A1 (en) * 2012-01-05 2013-07-25 Guilford Frederick Timothy Liposomally encapsulated reduced glutathione for management of cancer and disruption of cancer energy cycles
US8853248B2 (en) 2012-04-05 2014-10-07 Hubert Maehr (1,2,3-triazolyl)sulfonyl derivatives
SG11201407337QA (en) 2012-05-08 2014-12-30 Onyx Therapeutics Inc Cyclodextrin complexation methods for formulating peptide proteasome inhibitors
CA2872958A1 (en) 2012-05-11 2013-11-14 Cipla Limited Pharmaceutical composition
EP2943224B1 (en) 2013-01-11 2020-01-01 Xellia Pharmaceuticals ApS Voriconazole inclusion complexes
EP2968595A2 (en) 2013-03-14 2016-01-20 Fresenius Kabi USA LLC Voriconazole formulations
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
CN103690968A (zh) * 2013-11-21 2014-04-02 石药集团中奇制药技术(石家庄)有限公司 一种伏立康唑组合物及其制备方法
PT109117B (pt) * 2016-01-28 2019-02-01 Hovione Farm Sa Complexação de ingredientes ativos farmacêuticos
CN110022857A (zh) 2016-11-18 2019-07-16 艾库里斯抗感染治疗有限公司 基于改性环糊精和酸化剂的脒取代β-内酰胺化合物的新制剂、其制备及作为抗微生物药物组合物的用途
WO2018149359A1 (zh) * 2017-02-17 2018-08-23 武汉朗来科技发展有限公司 三氮唑抗菌衍生物、其药物组合物和用途
CN113750034A (zh) * 2020-06-05 2021-12-07 中南大学湘雅三医院 耳用温敏凝胶及其制备方法
CN116570558B (zh) * 2023-06-21 2023-12-26 广州仁恒医药科技股份有限公司 一种伏立康唑眼用纳米缓释组合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
DE3347421A1 (de) 1983-12-29 1985-07-11 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von fluorarmen alkaliphosphatloesungen
GB8819308D0 (en) * 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9002375D0 (en) * 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
GB9512961D0 (en) * 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
UA57083C2 (uk) 2003-06-16
NO995565L (no) 1999-11-30
UY25055A1 (es) 2000-12-29
PL191295B1 (pl) 2006-04-28
DE69814091D1 (de) 2003-06-05
EP1001813B8 (en) 2014-02-12
PA8453201A1 (es) 2000-05-24
IS2004B (is) 2005-04-15
NO995565D0 (no) 1999-11-12
ES2195355T3 (es) 2003-12-01
BR9809468A (pt) 2000-06-20
BR9809468B1 (pt) 2013-11-12
SI1001813T1 (en) 2004-02-29
JP2000513029A (ja) 2000-10-03
BRPI9809468B8 (pt) 2022-01-18
CN1125653C (zh) 2003-10-29
ZA985364B (en) 1999-12-20
AP912A (en) 2001-12-08
CZ289570B6 (cs) 2002-02-13
CZ409699A3 (cs) 2000-02-16
TNSN98090A1 (fr) 2005-03-15
IL132918A0 (en) 2001-03-19
CN1261287A (zh) 2000-07-26
DK1001813T3 (da) 2003-07-28
NO313125B1 (no) 2002-08-19
EP1001813A1 (en) 2000-05-24
CA2295035C (en) 2005-04-19
AP9801268A0 (en) 1998-06-30
NZ501066A (en) 2001-01-26
WO1998058677A1 (en) 1998-12-30
EA199900937A1 (ru) 2000-08-28
JP5089004B2 (ja) 2012-12-05
HUP0003323A2 (hu) 2001-06-28
DZ2523A1 (fr) 2003-02-01
IS5248A (is) 1999-11-15
HK1027966A1 (en) 2001-02-02
SK282946B6 (sk) 2003-01-09
AR015900A1 (es) 2001-05-30
GB9713149D0 (en) 1997-08-27
HRP980341A2 (en) 1999-02-28
ID22939A (id) 1999-12-16
BG103882A (en) 2000-07-31
BG64584B1 (bg) 2005-08-31
SA98190159B1 (ar) 2005-12-21
HUP0003323A3 (en) 2002-01-28
HRP980341B1 (en) 2001-12-31
ME00907B (me) 2007-08-03
MY118151A (en) 2004-09-30
EA001924B1 (ru) 2001-10-22
MA26508A1 (fr) 2004-12-20
SK159399A3 (en) 2000-06-12
JP2002332234A (ja) 2002-11-22
DE69814091T2 (de) 2004-01-22
KR100372988B1 (ko) 2003-02-25
PE84899A1 (es) 1999-09-17
TW406023B (en) 2000-09-21
HU228338B1 (en) 2013-03-28
IL132918A (en) 2001-09-13
PT1001813E (pt) 2003-07-31
PL337692A1 (en) 2000-08-28
CA2295035A1 (en) 1998-12-30
TR199903191T2 (xx) 2000-09-21
ATE238812T1 (de) 2003-05-15
AU724799B2 (en) 2000-09-28
US6632803B1 (en) 2003-10-14
EP1001813B1 (en) 2003-05-02
EG23910A (en) 2007-12-30
KR20010014006A (ko) 2001-02-26
CO4940450A1 (es) 2000-07-24
AU8110498A (en) 1999-01-04
OA11232A (en) 2003-05-26
YU68199A (sh) 2002-06-19

Similar Documents

Publication Publication Date Title
RS49633B (sr) Farmaceutske formulacije koje sadrže vorikonazol
JP4202273B2 (ja) フマギロール誘導体又はその塩の包接化合物、及び該包接化合物を含む医薬組成物
US7678776B2 (en) Inclusion complexes of butylphthalide with cyclodextrin or its derivatives, a process for their preparation and the use thereof
MXPA04012426A (es) Preparacion liquida que contiene oligopeptidos.
KR20160115827A (ko) 인돌 화합물을 포함하는 제제 및 이의 제조 방법
CA2486571C (en) Pharmaceutical composition
KR20090069264A (ko) 주사 투여용 약제학적 조성물
MXPA99012075A (en) Pharmaceutical formulations containing voriconazole
HK1027966B (en) Pharmaceutical formulations containing voriconazole
JPH02172913A (ja) ポリプレニル系化合物含有注射剤
HK1081451B (en) Medicinal composition